LMAT

LeMaitre Vascular Inc

LMAT, USA

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

https://www.lemaitre.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

0.2

Next Payout:

Dec 4, 2025

Yield:

0.9629 %
LMAT
stock
LMAT

Support Test: What Wall Street predicts for LMAT stock price - July 2025 Summary & Fast Exit/Entry Strategy Plans moha.gov.vn

Read more →
LMAT
stock
LMAT

(LMAT) Movement as an Input in Quant Signal Sets news.stocktradersdaily.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$104.3333

Analyst Picks

Strong Buy

3

Buy

2

Hold

6

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Low

35.75

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

5.35

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

4.58 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.90 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

43.38 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

High

0.58

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 98.67% of the total shares of LeMaitre Vascular Inc

1.

BlackRock Inc

(14.0509%)

since

2025/06/30

2.

Conestoga Capital Advisors, LLC

(7.0835%)

since

2025/06/30

3.

Vanguard Group Inc

(7.077%)

since

2025/06/30

4.

iShares Core S&P Small-Cap ETF

(5.4014%)

since

2025/08/31

5.

Conestoga Small Cap Investors

(4.9286%)

since

2025/07/31

6.

Copeland Capital Management, LLC

(4.3734%)

since

2025/06/30

7.

Geneva Capital Management

(4.043%)

since

2025/06/30

8.

State Street Corp

(3.58%)

since

2025/06/30

9.

Congress Asset Management Company, LLP

(2.9772%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(2.8366%)

since

2025/07/31

11.

First Trust Advisors L.P.

(2.7036%)

since

2025/06/30

12.

First Trust SMID Cp Rising Div Achv ETF

(2.5575%)

since

2025/08/28

13.

Geode Capital Management, LLC

(2.2962%)

since

2025/06/30

14.

Conestoga Small Cap Growth

(2.2944%)

since

2025/06/30

15.

Ranger Investment Management LP

(2.2709%)

since

2025/06/30

16.

iShares Russell 2000 ETF

(2.2257%)

since

2025/08/31

17.

Dimensional Fund Advisors, Inc.

(2.0365%)

since

2025/06/30

18.

Morgan Stanley - Brokerage Accounts

(1.8049%)

since

2025/06/30

19.

Congress Small Cap Growth Institutional

(1.7007%)

since

2025/07/31

20.

Ranger Small Cap

(1.5867%)

since

2025/06/30

21.

Northern Trust Corp

(1.516%)

since

2025/06/30

22.

Nationwide Geneva Small Cap Gr Instl Svc

(1.4158%)

since

2025/07/31

23.

Royal Bank of Canada

(1.3766%)

since

2025/06/30

24.

Envestnet Asset Management Inc

(1.3454%)

since

2025/06/30

25.

Millennium Management LLC

(1.2825%)

since

2025/06/30

26.

Rockefeller Capital Management L.P.

(1.2787%)

since

2025/06/30

27.

T. Rowe Price Associates, Inc.

(1.271%)

since

2025/06/30

28.

Acadian Asset Management LLC

(1.137%)

since

2025/06/30

30.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9731%)

since

2025/07/31

31.

T. Rowe Price Integrated US Sm Gr Eq

(0.9325%)

since

2025/07/31

32.

T. Rowe Price Integrated US SmCapGrEq

(0.9325%)

since

2025/06/30

33.

Fidelity Small Cap Index

(0.9248%)

since

2025/06/30

34.

iShares Russell 2000 Growth ETF

(0.8086%)

since

2025/08/31

35.

JNL Multi-Manager Small Cap Growth A

(0.8052%)

since

2025/06/30

36.

KAR Small-Mid Cap Growth

(0.8052%)

since

2025/07/31

38.

iShares S&P Small-Cap 600 Growth ETF

(0.781%)

since

2025/08/31

39.

Multi-Manager Small Cap Eq Strat Inst

(0.7498%)

since

2025/07/31

40.

DF Dent Small Cap Growth

(0.634%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.6347

Latest Release

Date

2025-09-30

EPS Actual

0.75

EPS Estimate

0.5667

EPS Difference

0.1833

Surprise Percent

32.3452%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(9)
Dividend
Decent Dividend Payer(4)
Economic Moat
Wide Moat Company(8.3)
GARP
Fair GARP(5)
Growth
Moderate Growth(4)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(8)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.